Drug Database
GL

glucagon (GlucaGen / GlucaGen Hypokit / Glucagon G)

✓ Approved

Eisai Co., Ltd. · GCGR · 重组蛋白

什么是 glucagon?

glucagon 是一种重组蛋白,由Eisai Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名GlucaGen, GlucaGen Hypokit, Glucagon G
公司Eisai Co., Ltd.
药物类别重组蛋白
分子靶点GCGR
给药途径Injectable (Others), Intramuscular (IM) Injection, Intravenous (IV), Subcutaneous Injection
状态Approved

作用机制

分子靶点

glucagon 作用于 1 个分子靶点:

GCGRglucagon receptor (GL-R, GGR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

glucagon 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersGastrointestinal mucosal necrosis✓ Approved
Metabolism and nutrition disordersHypoglycaemia✓ Approved

相关研究文献

PubMedPopulation health management2026-11-19

When Clinical Innovation Outpaces Implementation: A Dual Diffusion Model for GLP-1 Therapy and Employer Cardiometabolic Health.

Halterman Steven L SL

Glucagon-like peptide-1 (GLP-1)-based and related incretin therapies have rapidly expanded from glycemic management to obesity and broader cardiovascular-kidney-metabolic care. Their population-health impact, however, depends on more than therapeutic efficacy. Translation into durable benefit requires clinicians to identify and manage appropriate patients, benefit systems to enable effective access, and patients to initiate and sustain treatment. This review applies diffusion of innovations theory to propose a dual diffusion model for GLP-1 therapy and employer cardiometabolic health. The model conceptualizes provider implementation and employer/plan effective access as interdependent organizational diffusion processes that converge on the patient treatment trajectory. Their interaction produces 4 implementation states: implementation failure, identification gap, access gap, and integrated opportunity. Employer/plan effective access is proposed as a construct extending beyond binary coverage to include eligibility, affordability, utilization management, provider access, administrative feasibility, continuity, and treatment-support infrastructure. The model further distinguishes treatment initiation from sustainability and introduces system-generated discontinuation as a conceptual description of treatment cessation driven by structural barriers. Clinically Integrated cardiometabolic optimization is proposed as an implementation architecture positioning pharmacotherapy within coordinated longitudinal management of cardiometabolic risk rather than as an isolated pharmacy intervention. Seven propositions define a research agenda for testing the model. As incretin therapies expand across cardiometabolic indications, closing the efficacy-to-implementation gap may become as consequential as further gains in pharmacologic efficacy.

PMID 43053482
阅读全文 →
PubMedBMC infectious diseases2026-11-19

Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of incident infection and severe infection-related outcomes in type 2 diabetes.

Wu Jheng-Yan JY, Lee Keng-Wei KW, Huang Sheng-Chi SC, Chang Hsuan-Yuan HY et al.

Patients with type 2 diabetes mellitus (T2DM) are at increased risk of infection-related morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may exert immunomodulatory effects beyond glycemic control. Tirzepatide, a dual glucose-dependent insulinotropic peptide and GLP-1 receptor agonist, has demonstrated superior metabolic efficacy, but its association with infection-related outcomes remains unclear. We conducted a retrospective cohort study using the TriNetX research network including adults with T2DM between January 2022 and November 2025. New users of tirzepatide were compared with new users of GLP-1RAs. Propensity score matching (1:1) balanced demographic characteristics, comorbidities, medications, and laboratory variables. The primary endpoint was a composite of infection-related events within 1 year. Secondary outcomes included pneumonia, skin infection, and all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs). After matching, 143,288 patients were included in each group. Tirzepatide initiation was associated with a modestly lower risk of composite infection-related events compared with GLP-1RAs (HR 0.97, 95% CI 0.95-0.99). Lower risks were observed for pneumonia (HR 0.95, 95% CI 0.92-0.98), skin infection (HR 0.96, 95% CI 0.93-0.99), and all-cause mortality (HR 0.89, 95% CI 0.82-0.98). Results were consistent across most prespecified subgroups and sensitivity analyses, including landmark analyses and a negative control outcome. No significant differences were observed for acute pyelonephritis or gastrointestinal infection. In this large real-world cohort of patients with T2DM, tirzepatide use was associated with a modestly lower risk of infection-related outcomes compared with GLP-1RAs. These findings suggest that dual GIP/GLP-1 receptor agonism may be associated with differences in infection-related outcomes, although prospective studies are needed to confirm causality.

PMID 43052794
阅读全文 →
PubMedDiabetes, obesity & metabolism2026-11-19

Insulin Secretion Modelling to Characterize Post-Bariatric Hypoglycaemia After Roux-en-Y Gastric Bypass.

Mohammadi-Asl E E, El Fathi A A, Pei L L, Saeed H H et al.

Roux-en-Y Gastric Bypass (RYGB) is an effective treatment for obesity and Type 2 diabetes. Some individuals develop postprandial hypoglycaemia, termed post-bariatric hypoglycaemia (PBH). PBH is associated with marked postprandial increases in incretin and insulin levels. This study investigates how insulin secretion differs between post-RYGB patients with and without hypoglycaemia by identifying key secretion parameters. Insulin secretion was modelled using plasma glucose, insulin and C-peptide concentration data obtained from mixed meal tolerance test in three cohorts: healthy individuals without a history of upper gastrointestinal surgery (controls, n = 11), post-RYGB individuals without hypoglycaemia (RYGB-non-hypo, n = 18) and post-RYGB individuals with hypoglycaemia (RYGB-PBH, n = 20). Meal-driven insulin secretion differed across groups (p = 0.008) and was significantly higher in RYGB-PBH than controls (0.23 vs. 0.14 pmol/mg, p = 0.006), but not in RYGB-non-hypo (0.22, p = 0.071). Glucose-driven insulin secretion decreased in RYGB-non-hypo (0.04 vs. 0.07 pmol/kg/min per mg/dL, p = 0.005) but did not differ from controls in RYGB-PBH (0.08, p = 0.948), differing significantly between the two post-RYGB groups (p < 0.001). Meal absorption was significantly faster in both post-RYGB groups (9.08 and 8.44 vs. 11.48 min, both p < 0.001). Models fit plasma insulin and C-peptide well (mean joint nRMSE: 0.60-0.92 across groups). Parameters were estimated with good precision (CV < 100%). Insulin secretion dynamics differ between post-RYGB patients with and without hypoglycaemia. Both groups showed faster meal absorption and a shift towards higher meal-driven secretion, significant only in RYGB-PBH, but only those without hypoglycaemia showed a reduction in glucose-driven secretion. This PBH model can support in silico development of glucagon-based interventions.

PMID 43053530
阅读全文 →
PubMedRespiratory research2026-11-19

Association between sodium-glucose cotransporter 2 inhibitors and the risk of chronic lower respiratory disease in type 2 diabetes mellitus: findings from two target trial emulations.

Li Yuhao Y, Lv Yiqiao Y, Dai Yongqi Y, Zeng Huatang H et al.

Research on the association between sodium‑glucose cotransporter 2 inhibitors (SGLT-2i) and chronic lower respiratory diseases (CLRDs) in patients with type 2 diabetes (T2DM) remains limited. This study aimed to investigate this association and examine the potential modifying effects such as age, sex, and diabetes severity. Using the Shenzhen Public Health Data Platform, we conducted two independent target trial emulations with a new‑user active comparator design, comparing SGLT‑2i with glucagon‑like peptide‑1 receptor agonists (GLP-1RA) and dipeptidyl peptidase‑4 inhibitors (DPP‑4i), respectively. The primary outcome was incident CLRD; secondary outcomes included five subtypes-bronchitis, bronchiectasis, asthma, chronic obstructive pulmonary disease, and emphysema. Overlap-weighted Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). During a median follow-up of 1.76 years, 349 (7.95%) and 397 (9.04%) new CLRD cases occurred in SGLT-2i and GLP-1RA users, respectively. Compared with GLP-1RA, SGLT-2i use was associated with a lower CLRD incidence (HR 0.87, 95% CI 0.79-0.96), primarily driven by reduced risk of bronchitis (HR: 0.89; 95% CI: 0.79-1.00) and asthma (HR: 0.77; 95% CI: 0.58-1.01); no significant associations were found for other subtypes. Compared with DPP-4i, SGLT-2i use showed a trend toward lower CLRD risk (HR: 0.95; 95% CI: 0.91-0.99), with significant reductions for bronchitis (HR: 0.95; 95% CI: 0.91-1.00), bronchiectasis (HR: 0.86; 95% CI: 0.75-1.00), and asthma (HR: 0.87; 95% CI: 0.77-0.98). Subgroup analyses indicated significant interactions for bronchiectasis by sex (P interaction = 0.001). Compared with GLP-1 RA, SGLT-2i were associated with a significantly lower risk of CLRDs, driven predominantly by bronchitis; versus DPP-4i, the risk reduction was primarily observed for bronchitis, bronchiectasis, and asthma. The protective association between SGLT-2i use and bronchiectasis was more pronounced in females than in males relative to DPP-4i.

PMID 43053103
阅读全文 →
PubMedJournal of anaesthesiology, clinical pharmacology2026-11-18

Glucagon-like peptide-1 receptor agonists in the perioperative period: Navigating the evidence, minimizing harm, and finding the way forward.

Trikha Anjan A, Khalil Mohamed M

PMID 43048413
阅读全文 →
PubMedEuropean journal of nutrition2026-11-18

Intragastric administration of the bitter tastant, quinine, reduces postprandial plasma glucose without affecting gastric emptying in health.

Ghorbaninejad Parivash P, Moradi Maedeh M, Bitarafan Vida V, Fitzgerald Penelope Ce PC et al.

In health and type 2 diabetes, intraluminal administration of quinine stimulates glucoregulatory hormones and slows gastric emptying, key determinants of postprandial plasma glucose, following oral carbohydrate. We have now investigated these effects following a mixed solid-liquid meal, with gastric emptying quantified using scintigraphy, the 'gold-standard' technique. On three separate days, nine middle-aged individuals without diabetes (age: 51 ± 8 years) received 0 ('control'), 300 ('Q300') or 600 ('Q600') mg quinine hydrochloride intragastrically, 60 min before a standardised mixed solid-liquid meal (100 g beef burger radiolabelled with 99mTc-phytate and 150 mL 10% glucose drink radiolabelled with 67Ga-EDTA), in randomised, double-blind fashion. Plasma glucose, insulin and glucagon were measured at baseline, for 60 min before, and for 120 min after, the meal. Gastric emptying was measured using scintigraphy. Data were analysed using repeated-measures ANOVA. Q600 and Q300 both reduced plasma glucose immediately before the meal, at t=-5 min, as well as overall and peak postprandial glucose, when compared with control, in a dose-dependent manner (P < 0.05). Q600 stimulated plasma insulin before the meal at t=-20 min (P = 0.04), and the postprandial plasma insulin-to-glucose ratio (P = 0.02), compared with control. Both overall and peak postprandial plasma glucose were inversely related to plasma insulin at t=-20 min (R<-0.51, P < 0.05). Quinine did not affect plasma glucagon or gastric emptying. Intragastric quinine lowers the plasma glucose response to a mixed solid-liquid meal in middle-aged individuals without diabetes by stimulating preprandial insulin, without affecting either plasma glucagon or gastric emptying. The study was registered as a clinical trial with the Australian and New Zealand Clinical Trials Registry ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=383933&isReview=true ; ACTRN12622000735752, date of registration: May 23, 2022).

PMID 43049790
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多glucagon